| |
Monday, December 16, 2024 | 1pm ET / 10am PT Join us for an insightful webinar on the evolving privacy landscape impacting pharma marketers. As state laws continue to shape advertising practices, understanding the nuances of compliance and data ethics is crucial. Register now to gain access to expert insights on sustainable privacy strategies and balancing innovation with ethical data use.
|
|
Today’s Big NewsDec 9, 2024 |
|
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now.
|
|
| By Angus Liu GSK’s antibody-drug conjugate Blenrep has mounted a sizable patient survival benefit among certain multiple myeloma patients in a head-to-head comparison against Johnson & Johnson’s industry-leading Darzalex. |
|
|
|
By Nick Paul Taylor Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate, trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low dose into phase 3. |
By Conor Hale After securing Medicare coverage this year for its kIQ wearable neurostimulator, Cala raised $50 million to boost its commercial trajectory. |
By Ben Adams Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO). The company is looking to consolidate its older drug, Nuplazid, while boosting its new offering, Daybue. |
|
The right funding at the right time is crucial for life sciences companies that want to fuel innovation and scale operations. Download this free whitepaper to drive innovation, expand operations and lead your organization to further success.
|
|
By Kevin Dunleavy Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. But after flunking three clinical trials with the combination, the company has emerged with a tepid win with the pairing hitting the primary endpoint in an ovarian cancer study. |
By Nick Paul Taylor AbbVie has completed a hat trick of phase 3 wins for its Parkinson’s disease prospect tavapadon, teeing the drugmaker up to file for FDA approval of drug candidate in 2025. |
By Andrea Park A new survey from AbbVie digs into the emotional experience of a chronic lymphocytic leukemia diagnosis and, according to the company, is the first to break down the results by race/ethnicity to highlight the differing mental health impacts and desired support resources for patients of diverse backgrounds. |
By Angus Liu Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its Calquence can work in newly diagnosed chronic lymphocytic leukemia. |
By Darren Incorvaia After a data monitoring committee found that the Reliance II study of REL-1017 is unlikely to hit its primary endpoint, Relmada Therapeutics is scrapping both the Reliance II and Relight phase 3 trials of REL-1017 in major depressive disorder (MDD), the company announced on Dec. 9. |
By Andrea Park ViiV Healthcare wants people to go deep when talking about HIV rather than merely skimming the surface of the experience of living with the condition. |
By Fraiser Kansteiner On Friday, Catalent and Novo Holdings said the European Commission granted “unconditional approval” to the companies’ pending $16.5 billion merger. With Europe’s blessing, Novo Holdings and Catalent now need to get a thumbs up from the U.S. Federal Trade Commission for their deal to pass muster. |
By James Waldron It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping its phase 2-stage obesity prospect barely two months after going public. |
By Nick Paul Taylor Omnicom has struck a deal to merge with Interpublic Group, bringing together marketing and sales firms that generated a combined $3.7 billion in pharmaceuticals and healthcare revenues over the first three quarters of 2024. |
By Gabrielle Masson For the second time this year, Carisma is laying off staff. The newly announced restructure includes several company leaders hitting the exit and the discontinuation of the biotech’s sole clinical candidate. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore the biotech IPO market rebound and ask: Is the momentum here to stay? |
|
|---|
|
|
|
The DMPK experts at QPS are ready to complete your next mass balance,
PK, ADME, MARG and/or QWBA study. Download the DMPK White Paper on the optimal methods of producing tissue distribution data and to learn more about QPS DMPK capabilities.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
